Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar- ranibizumab) for the Treatment of nAMD
Shots:
- The P-III study evaluates Byooviz (0.5 mg- IVT) vs ranibizumab in 634 patients with nAMD. The results will be presented at EURETINA 2021
- The 1EPs are changed from baseline in BCVA @8wks. and change in CST @4wks. with both EPs- followed by 52wks. The post-hoc analysis showed that the baseline age- BCVA- CST- and total lesion size were identified to be associated with the visual acuity & anatomical outcomes
- In subgroup analysis- similar visual outcomes of 2 products in change from baseline in BCVA in multiple subgroups were observed & support an equivalent clinical efficacy. Byooviz is an effective & valuable treatment option for nAMD patients globally
| Ref: Samsung Bioepis | Image: Samsung Bioepis
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
